These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 37069355)
21. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study. Grumet M; Sherman J; Dorf BS Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766 [TBL] [Abstract][Full Text] [Related]
22. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial. Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605 [TBL] [Abstract][Full Text] [Related]
23. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449 [TBL] [Abstract][Full Text] [Related]
25. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653 [TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Yao W; Shi L; Zhang Y; Dong H; Zhang Y Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737 [TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia. Hezam K; Mo R; Wang C; Liu Y; Li Z Curr Pharm Biotechnol; 2022; 23(9):1153-1167. PubMed ID: 34493193 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Harrell CR; Jovicic BP; Djonov V; Volarevic V Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176 [TBL] [Abstract][Full Text] [Related]
29. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Can A; Coskun H Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878 [TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019. Whittaker Brown SA; Iancu-Rubin C; Aboelela A; Abrahams A; Burke E; Drummond T; Grossman F; Itescu S; Lagdameo J; Lin JY; Mark A; Levine JE; Osman K Cytotherapy; 2022 Aug; 24(8):835-840. PubMed ID: 35649958 [TBL] [Abstract][Full Text] [Related]
31. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial. Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M; Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568 [TBL] [Abstract][Full Text] [Related]
32. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol. Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123 [TBL] [Abstract][Full Text] [Related]
33. Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment. Chinnici CM; Russelli G; Bulati M; Miceli V; Gallo A; Busà R; Tinnirello R; Conaldi PG; Iannolo G World J Gastroenterol; 2021 May; 27(17):1905-1919. PubMed ID: 34007129 [TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy. Barros I; Silva A; de Almeida LP; Miranda CO Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585 [TBL] [Abstract][Full Text] [Related]
35. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial. McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981 [TBL] [Abstract][Full Text] [Related]
36. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS. Aitong W; Leisheng Z; Hao Y Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927 [TBL] [Abstract][Full Text] [Related]
37. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19. Kaye RJ Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797 [TBL] [Abstract][Full Text] [Related]